Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00332124
Recruitment Status : Completed
First Posted : June 1, 2006
Last Update Posted : September 2, 2020
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether choline supplementation has an effect on infant development.

Condition or disease Intervention/treatment Phase
Pregnancy Child Development Drug: Choline Dietary Supplement: Placebo Phase 1

Detailed Description:

Choline is an essential nutrient that can be found in foods, such as egg yolks, liver, and other meats. It is important for the composition and repair of normal cellular membranes, normal brain function, and normal cardiovascular function. Research has suggested that the presence of adequate amounts of choline during pregnancy and breastfeeding can help ensure healthy fetal brain development. Additionally, adequate prenatal choline levels may have long-lasting positive effects on cognitive function, including memory. However, sufficient research has not been done on the effects of choline on pregnant women and their unborn babies. This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether taking choline during pregnancy will have an effect on infant development.

Participants in this double-blind study will be randomly assigned to receive either placebo or 900 mg of choline daily throughout pregnancy, until delivery. Babies will then begin receiving either placebo or choline daily from the time of birth until they are 3 months old. Participants will attend a baseline study visit that will include eligibility assessment, urine collection, measurement of vital signs, dispensing of study medication, and an ultrasound. Subsequent study visits will occur every 4 weeks throughout pregnancy and 6 months postpartum. Vital signs will be taken, urine samples will be collected, and study medication will be given at each visit. Two blood samples will be taken between Weeks 32 and 36 of gestation. Heel sticks will be performed on babies when they are 4 and 12 weeks old. Follow-up visits will be held every 6 months until the baby is 18 months old.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 351 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels
Actual Study Start Date : June 2006
Actual Primary Completion Date : March 2017
Actual Study Completion Date : March 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pregnancy

Arm Intervention/treatment
Placebo Comparator: 1
Participants will take placebo
Dietary Supplement: Placebo
Corn oil every day in place of choline

Active Comparator: 2
Participants will take choline
Drug: Choline
900 mg every day until birth of infant
Other Name: Polyenylphosphatidylcholine

Primary Outcome Measures :
  1. Sensory Gaiting (P50) [ Time Frame: Measured at birth, 1 month and 3 months after birth ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pregnant
  • Between 10 and 18 weeks gestational age
  • Healthy
  • Diagnosis of psychosis

Exclusion Criteria:

  • Use of any tobacco or nicotine product
  • Drinks more than 1 alcoholic drink per day
  • Use of illicit drugs
  • History of trimethylaminuria
  • History of kidney disease
  • History of liver disease
  • History of pre-pregnancy diabetes
  • History of Parkinson's disease
  • History of fetal death, fetal/infant congenital malformation, or fetal/infant genetic abnormality
  • Evidence of noncompliance to study medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00332124

Layout table for location information
United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Layout table for investigator information
Principal Investigator: Robert Freedman, MD University of Colorado, School of Medicine,
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of Colorado, Denver Identifier: NCT00332124    
Other Study ID Numbers: 04-0678
First Posted: June 1, 2006    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: August 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Lipotropic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Lipid Regulating Agents
Nootropic Agents